LLA vs. DXRX, AGL, YGEN, ABDX, GDR, PRM, GENI, VRCI, LLAI, and IDHC
Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), genedrive (GDR), Proteome Sciences (PRM), GENinCode (GENI), Verici Dx (VRCI), LungLife AI (LLAI), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.
LLA.L,0P0001T9GN,0 vs.
LLA.L,0P0001T9GN,0 (LON:LLA) and Diaceutics (LON:DXRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to Diaceutics' net margin of -10.90%. Diaceutics' return on equity of -7.13% beat LLA.L,0P0001T9GN,0's return on equity.
Diaceutics has a consensus price target of GBX 160, indicating a potential upside of 27.49%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than LLA.L,0P0001T9GN,0.
In the previous week, Diaceutics had 6 more articles in the media than LLA.L,0P0001T9GN,0. MarketBeat recorded 6 mentions for Diaceutics and 0 mentions for LLA.L,0P0001T9GN,0. Diaceutics' average media sentiment score of 0.10 beat LLA.L,0P0001T9GN,0's score of 0.00 indicating that Diaceutics is being referred to more favorably in the news media.
Diaceutics received 15 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.
LLA.L,0P0001T9GN,0 has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Diaceutics has higher revenue and earnings than LLA.L,0P0001T9GN,0. Diaceutics is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.
5.4% of LLA.L,0P0001T9GN,0 shares are owned by institutional investors. Comparatively, 52.4% of Diaceutics shares are owned by institutional investors. 34.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Diaceutics beats LLA.L,0P0001T9GN,0 on 14 of the 16 factors compared between the two stocks.
Get LLA.L,0P0001T9GN,0 News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LLA.L,0P0001T9GN,0 Competitors List
Related Companies and Tools
This page (LON:LLA) was last updated on 12/22/2024 by MarketBeat.com Staff
